This article covers stocks trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks associated with these stocks.
The word alone makes you shiver.
Every year, there are approximately 230,000 women diagnosed with breast cancer in the United States. According to the National Cancer Institute, of these women, about 75% test positive for HER2 (IHC 1+, 2+ or 3+). Out of these, only 25% of all breast cancer patients, those with HER2 3+ disease, are eligible for Herceptin®, from Roche (OTCQX:RHBY) and Genentech, which had revenues of over $6 billion in 2012.
The remaining 50% of low HER 2 expressing patients, or those that...
Only subscribers can access this article, which is part of the PRO research library covering 3,575 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: